Skip to Content


Active Substance: levacetylmethadol
Common Name: levacetylmethadol
ATC Code: N02AC
Marketing Authorisation Holder: Sipaco Internacional Lda.
Active Substance: levacetylmethadol
Status: Withdrawn
Authorisation Date: 1997-07-01
Therapeutic Area: Opioid-Related Disorders
Pharmacotherapeutic Group: Analgesics

Therapeutic Indication

ORLAAM is indicated for the substitution maintenance treatment of opiate addiction in adults previously treated with methadone, as part of a comprehensive treatment plan including medical, social and psychological care.

ORLAAM should be administered under the supervision of physicians with experience in addiction treatment and whenever practicable, in centres specialising in the treatment of drug addiction.

ORLAAM is not intended for take home use.

The marketing authorisation for Orlaam has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.